Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis

BACKGROUND: The efficacy of nirmatrelvir plus ritonavir (NMV-r) for vaccinated COVID-19 patients at high risk of progression is not adequately recognised. To address this gap, we conducted a systematic review and meta-analysis of current literature. METHODS: We searched PubMed, Web of Science, Embas...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huamin, Xiang, Huairong, He, Bei, Zhang, Qizhi, Peng, Wenxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Global Health 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357131/
https://www.ncbi.nlm.nih.gov/pubmed/37469290
http://dx.doi.org/10.7189/jogh.13.06032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357131/
https://www.ncbi.nlm.nih.gov/pubmed/37469290
http://dx.doi.org/10.7189/jogh.13.06032

Ejemplares similares